1例NTRK重排的巨大纵膈梭形细胞瘤病例报告
One Case Report of Giant Mediastinal Spindle Cell Tumor with NTRK Rearrangement
DOI: 10.12677/acm.2024.1451651, PDF,   
作者: 陈毓新:山东大学齐鲁医学院,山东 济南;山东省立医院胸外科,山东 济南;刘相燕*:山东大学齐鲁医学院,山东 济南;山东省立医院胸外科,山东 济南;山东第一医科大学附属省立医院胸外科,山东 济南
关键词: 神经原肌球蛋白相关激酶梭形细胞瘤纵膈肿物NTRK Rearrangement Spindle Cell Neoplasm Mediastinum
摘要: 神经原肌球蛋白相关激酶(Neurotropomyosin-related kinase, NTRK)重排的梭形细胞肿瘤是世界卫生组织第五版软组织和骨肉瘤分类中的一类新肿瘤。迄今为止,很少有报告纵隔发生NTRK重排的梭形细胞瘤病例。因此,我们收集了一例巨大的(27 × 21 × 10 cm)纵膈NTRK重排的梭形细胞肿瘤病例。手术采取了保留肋骨的三切口开胸术。术后病理诊断为梭形细胞瘤。免疫组化结果显示,肿瘤组织中平滑肌肌动蛋白、S100、CD34、NTRK均呈阳性表达。通过讨论该病的病理类型、诊断和治疗,为其临床诊疗提供更多参考。
Abstract: Neurotropomyosin-related kinase (NTRK) rearranged spindle cell neoplasm (SCN) represents a new group of tumors included in the fifth edition of the World Health Organization (WHO) classification of soft tissue and bone sarcomas. To date, few cases of NTRK-rearranged SCN in the mediastinum in the mediastinum have been reported. Herein we present a case of a giant (27 × 21 × 10 cm) NTRK rearranged SCN in the right thoracic cavity removed through a special thoracotomy that preserves the rib. The neoplasm was removed surgically and was pathologically diagnosed as a spindle cell tumor. Immunohistochemistry results showed that smooth muscle actin (SMA), S100, CD34 and NTRK were positively expressed in tumor tissue. By discussing the pathologic types, diagnosis and treatment of the disease, we can provide more references for clinical diagnosis and treatment of this disease.
文章引用:陈毓新, 刘相燕. 1例NTRK重排的巨大纵膈梭形细胞瘤病例报告[J]. 临床医学进展, 2024, 14(5): 2063-2068. https://doi.org/10.12677/acm.2024.1451651

参考文献

[1] Anderson, W.J. and Doyle, L.A. (2021) Updates from the 2020 World Health Organization Classification of Soft Tissue and Bone Tumours. Histopathology, 78, 644-657. [Google Scholar] [CrossRef] [PubMed]
[2] Tsai, J.W., Lee, J.C., Hsieh, T.H., et al. (2022) Adult NTRK-Rearranged Spindle Cell Neoplasms of the Viscera: With an Emphasis on Rare Locations and Heterologous Elements. Modern Pathology, 35, 911-921. [Google Scholar] [CrossRef] [PubMed]
[3] Ghigna, M.R., Thomas, D.E. and Montperville, V. (2021) Mediastinal Tumours and Pseudo-Tumours: A Comprehensive Review with Emphasis on Multidisciplinary Approach. European Respiratory Review, 30, 200309. [Google Scholar] [CrossRef] [PubMed]
[4] Sbaraglia, M., Bellan, E. and Deitos, A.P. (2021) The 2020 WHO Classification of Soft Tissue Tumours: News and Perspectives. Pathologica, 113, 70-84. [Google Scholar] [CrossRef
[5] Cocco, E., Scaltaiti, M. and Driloon, A. (2018) NTRK Fusion-Positive Cancers and TRK Inhibitor Therapy. Nature Reviews Clinical Oncology, 15, 731-747. [Google Scholar] [CrossRef] [PubMed]
[6] Agaram, N.P., Zhang, L., Sung, Y.-S., et al. (2016) Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-Like Neural Tumors. American Journal of Surgical Pathology, 40, 1407-1416. [Google Scholar] [CrossRef
[7] Tauziede-Espariat, A., Duchesne, M., Baud, J., et al. (2023) NTRK-Rearranged Spindle Cell Neoplasms Are Ubiquitous Tumours of Myofibroblastic Lineage with a Distinct Methylation Class. Histopathology, 82, 596-607. [Google Scholar] [CrossRef] [PubMed]
[8] Hung, Y.P., Fletcher, C.D.M. and Hornick, J.L. (2018) Evaluation of Pan-TRK Immunohistochemistry in Infantile Fibrosarcoma, Lipofibromatosis-Like Neural Tumour and Histological Mimics. Histopathology, 73, 634-644. [Google Scholar] [CrossRef] [PubMed]
[9] Hechtman, J., Benayed, R., Hyman, D., et al. (2017) Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. American Journal of Surgical Pathology, 41, 1547-1551. [Google Scholar] [CrossRef
[10] Yin, L., Shi, C., He, X., et al. (2023) NTRK-Rearranged Spindle Cell Neoplasms: A Clinicopathological and Molecular Study of 13 Cases with Peculiar Characteristics at One of the Largest Institutions in China. Pathology, 55, 362-374. [Google Scholar] [CrossRef] [PubMed]
[11] Suurmeijer, A.J.H., Dickson, B.C., Swanson, D., et al. (2018) A Novel Group of Spindle Cell Tumors Defined by S100 and CD34 Co-Expression Shows Recurrent Fusions Involving RAF1, BRAF, and NTRK1/2 Genes. Genes Chromosomes Cancer, 57, 611-621. [Google Scholar] [CrossRef] [PubMed]
[12] Yasui, N., Yoshida, A., Kawamoto, H., et al. (2014) Clinicopathologic Analysis of Spindle Cell/Sclerosing Rhabdomyosarcoma. Pediatric Blood & Cancer, 62, 1011-1016. [Google Scholar] [CrossRef] [PubMed]
[13] Hong, D.S., Dubois, S.G., Kummar, S., et al. (2020) Larotrectinib in Patients with TRK Fusion-Positive Solid Tumours: A Pooled Analysis of Three Phase 1/2 Clinical Trials. The Lancet Oncology, 21, 531-540. [Google Scholar] [CrossRef
[14] Drilon, A., Laetsch, T.W., Kummar, S., et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England Journal of Medicine, 378, 731-739. [Google Scholar] [CrossRef
[15] Doebele, R.C., Drilon, A., Pazares, L., et al. (2020) Entrectinib in Patients with Advanced or Metastatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1-2 Trials. The Lancet Oncology, 21, 271-282. [Google Scholar] [CrossRef